Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia

OBJECTIVES: The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and...

Descripción completa

Detalles Bibliográficos
Autores principales: Vreman, Rick A., Geenen, Joost W., Hövels, Anke M., Goettsch, Wim G., Leufkens, Hubert G. M., Al, Maiwenn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885502/
https://www.ncbi.nlm.nih.gov/pubmed/31317510
http://dx.doi.org/10.1007/s40258-019-00496-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885502/
https://www.ncbi.nlm.nih.gov/pubmed/31317510
http://dx.doi.org/10.1007/s40258-019-00496-1

Ejemplares similares